Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin AmyloidosisDavid Adams, Ole B. Suhr, Ivailo Tournev et al.|New England Journal of Medicine|2018Cited by 2.9k
Inotersen Treatment for Patients with Hereditary Transthyretin AmyloidosisMerrill D. Benson, Teresa Coelho, Márcia Waddington‐Cruz et al.|New England Journal of Medicine|2018Cited by 1.4k
Wnt Pathway Activation in Long Term Remnant Rat ModelElisenda Bañón-Maneus, Josep M. Campistol|BioMed Research International|2014Cited by 5